At 8.9% CAGR, Europe Poultry Vaccines Market is Projected to be Worth US$ 635.01 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Europe poultry vaccines market was valued at US$ 321.82 million in 2023 and is anticipated to reach US$ 635.01 million by 2031, registering a CAGR of 8.9% from 2023 to 2031. Government support for mass vaccination drives and innovative schemes and advancements in vectored and combination vaccines are among the critical factors attributed to drive the Europe poultry vaccines market growth.

Government worldwide is supportive against poultry vaccination with rising Global Burden of Disease (GBD). The support involves launching of mass vaccination schemes and several vaccination programs at vaccination centers or through door-step immunization services. 

• In April 2023, the government of France announced passing a tender for ordering 80 million doses of avian influenza vaccines as the country was preparing for a mass vaccination program. The "ANES" Ministry in France was the first country in the European Union (EU) to start such a mass vaccination scheme. For conducting such a mass vaccination drive, France mandated 2 companies, France's Ceva Animal Health and Germany's Boehringer Ingelheim, to develop avian influenza vaccines. Both vaccines by the two companies effectively protect birds against the virus.

• In recent years, there has been an outbreak of highly pathogenic avian influenza (HPAI) in both domestic and wild birds throughout the European Union (EU). In order to stop and manage the spread of HPAI, vaccination may be taken into consideration in addition to currently in place strategies (such as surveillance, biosecurity, and early identification). As mandated by EU regulation, post-vaccination improved surveillance of vaccinated poultry is necessary to show that vaccinated areas are free of HPAI and to identify any possible outbreaks of the virus early on. In May 2024, MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA announced that the INNOVAX-ND-H5 vaccination for chickens has received marketing authorization from the European Commission. This vaccination protects poultry from the avian influenza virus strains of clade 2.3.4.4b that are currently in circulation, which have a high fatality rate. It is the first vaccination to be centrally registered in the European Union. Any vaccination against HPAI should be administered in compliance with government rules and tandem with stringent biosecurity and surveillance measures.

Therefore, such government support for mass vaccination drives and designing innovative schemes is anticipated to provide lucrative opportunities for the poultry market growth in the coming years.

On the contrary, vaccination failure and improper handling hampers the growth of Europe poultry vaccines market.

Based on type, the Europe poultry vaccines market is bifurcated into broiler and layer. The broiler segment held 58.3% market share in 2023, amassing US$ 187.49 million. It is projected to garner US$ 380.86 million by 2031 to register 9.3% CAGR during 2023–2031.

In terms of technology, the Europe poultry vaccines market is segmented into live attenuated vaccines, inactivated vaccines, and recombinant vaccines. The live attenuated vaccines segment held 51.2% share of Europe poultry vaccines market in 2023, amassing US$ 164.71 million. It is projected to garner US$ 329.55 million by 2031 to register 9.1% CAGR during 2023–2031.

By dosage form, the Europe poultry vaccines market is segmented into liquid vaccines, freeze-dried vaccines, and dust/powdered form vaccines. The liquid vaccines segment held 53.1% share of Europe poultry vaccines market in 2023, amassing US$ 170.88 million. It is projected to garner US$ 348.75 million by 2031 to expand at 9.3% CAGR from 2023 to 2031.

Based on type of disease, the Europe poultry vaccines market is categorized into avian influenza, infectious bronchitis, Marek's disease, avian salmonellosis, infectious bursal disease (IBD), Newcastle disease, and others. The avian influenza segment held 29.6% share of Europe poultry vaccines market in 2023, amassing US$ 95.16 million. It is predicted to garner US$ 197.39 million by 2031 to expand at 9.5% CAGR between 2023 and 2031.

By route of administration, the Europe poultry vaccines market is segmented into drinking water (D/W), intramuscular (I/M), subcutaneous (I/S), and others. The drinking water (D/W) segment held 41.9% share of Europe poultry vaccines market in 2023, amassing US$ 134.86 million. It is estimated to garner US$ 277.33 million by 2031 to expand at 9.4% CAGR during 2023–2031.

In terms of end user, the Europe poultry vaccines market is categorized into poultry farms & hatchery, veterinary hospitals, and poultry vaccination enters & clinics. The poultry farms & hatchery segment held 50.9% share of Europe hearing aids market in 2023, amassing US$ 163.73 million. It is projected to garner US$ 336.00 million by 2031 to expand at 9.4% CAGR from 2023 to 2031.

Based on country, the Europe poultry vaccines market is categorized into Germany, Spain, France, the UK, Italy, and the Rest of Europe. Our regional analysis states that Germany captured 29.9% share of Europe poultry vaccines market in 2023. It was assessed at US$ 96.06 million in 2023 and is likely to hit US$ 198.76 million by 2031, registering a CAGR of 9.5% during 2023–2031.

Key players operating in the Europe poultry vaccines market are Boehringer Ingelheim International GmbH, Zoetis Inc, BIOVAC, Phibro Animal Health Corp, Dechra Pharmaceuticals PLC, Elanco Animal Health Inc, Merck KGaA, Ceva, and Vaccinova AB, among others.

• In June 2023, Zoetis announced launching of "CircoMax" in Europe. This new product is the effective against Porcine Circovirus Type 2 (PCV2) vaccine that includes two genotypes (A and B) providing broad coverage and protection against PCV2 threat. Also, CircoMax has demonstrated protection against PCV2a, PCV2b, and PCV2d.
• In February 2019, Phibro Animal Health will introduce its new Provide Prime direct-fed microbial product that helps optimize the gut microbiome for improved health, immunity, and productivity in poultry. Provia™ Prime is in a class of Bacillus-based Direct-Fed Microbials (DFMs) that have been shown to promote beneficial gut bacteria, which can help improve immunity, foster gut health and act as natural growth promoters. It includes a patent-pending proprietary combination of four powerful probiotic strains of Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans and Bacillus amyloliquefaciens. Together these four strains create a synergistic effect that encourage a higher population in the gut of “good bacteria,” which can help support broiler health and increase yield.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com